Everolimus

reshuffle pipeline target reorganize shift change
Biotech

ITM shares details of radiotherapy's ph. 3 win, reveals OS miss

ITM provided more detail on how its radiotherapy bested standard of care while revealing the asset was unable to prove a benefit in overall survival.
James Waldron Mar 6, 2025 4:30am
spotlight purple blue light

Radioisotope manufacturer ITM grabs spotlight with phase 3 win

Jan 28, 2025 5:00am
NovartisHQClose

Novartis offloads phase 2 mTORC1 programs to PureTech

Mar 24, 2017 4:24am